Algert Global’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Algert Global’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-73,406	Closed	-$2.82M	–	1300
2023 Q2	$2.82M	Sell	73,406 -62,910	-46%	-$1.62M	0.12%	266
2023 Q1	$3.16M	Buy	136,316 +4,889	+4%	+$117K	0.15%	202
2022 Q4	$3.44M	Sell	131,427 -1,430	-1%	-$31.7K	0.19%	147
2022 Q3	$2.61M	Buy	132,857 +114,537	+625%	+$2.3M	0.16%	195
2022 Q2	$320K	Buy	+18,320	New	+$288K	0.02%	897
2019 Q2	–	Sell	-3,870	Closed	-$77K	–	416
2019 Q1	$77K	Buy	+3,870	New	+$67.5K	0.04%	286

Algert Global's KDNY Position: Q3 2023 in Review

Algert Global sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 73,406 shares — an estimated $2.82M sold.

Algert Global first reported a position in KDNY in Q1 2019 and held it in 6 quarters. The position peaked at $3.44M in Q4 2022. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Algert Global reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Algert Global sold 73,406 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $2.82M.
Algert Global first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2019 and held it in 6 quarters.
Algert Global's Chinook Therapeutics, Inc. Common Stock position peaked at $3.44M in Q4 2022.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Algert Global's 13F filing for Q3 2023, filed 13 Nov 2023.